Year: 2018
Language: Traditional Chinese
Author(s): Jenny Goudemand, Manuel Carcao
Also Available In: English, Spanish
This is not an official WFH translation. This resource has been translated with permission by a WFH National Member Organization (NMO), and is shared here with their kind permission. Translating organizations are encouraged to have translations reviewed by local experts, the WFH is not responsible for the translation or for any errors or changes to content from the original English edition. Patient organizations interested in translating a WFH resource must first obtain permission from the WFH, available here.
Inhibitors are a serious complication of hemophilia caused by an immune response to clotting factor concentrates. Treatment of inhibitors is one of the biggest challenges in hemophilia care today. This primer explains our current understanding of how and why inhibitors form, reviews the established approaches to managing inhibitors, and looks ahead to some potential future developments in the field.
In these sessions from the WFH 2022 World Congress, David Lillicrap, Len Valentino, Sophie Susen, Mrinal Gounder, Rebecca Kruse-Jarres, Christine
The development of inhibitory antibodies to therapeutic factor VIII (FVIII) in up to 40% of people with severe hemophilia A
In the Monday morning session entitled Inhibitors: Clinical Aspects, Jan Astermark described the different diagnostic assays laboratories can carry out
This resource has also been translated into the following languages, with permission from the WFH, by NMOs: Traditional Chinese Inhibitors
In the Monday afternoon session on alternative therapies in the management of inhibitors, Rebecca Kruse-Jarres discusses the latest developments in
In the Monday afternoon session on innovating immune tolerance induction for hemophilia, Shannon Meeks explains the mechanisms of inhibitors.